Antilipemic agent that lowers cholesterol and triglycerides. It decreases low density lipoproteins and increases high density lipoproteins.
For the treatment of primary hyperlipidaemia types IIa, IIb, III, IV and V (Fredrickson classification) corresponding to groups I, II and III of the European Atherosclerosis Society guidelines - when diet alone or improvements in lifestyle such as increased exercise or weight reduction do not lead to an adequate response. Also for the treatment of secondary hyperlipidaemias, e.g. severe hypertriglyceridemias, when sufficient improvement does not occur after correction of the underlying disorder (e.g. diabetes mellitus).
Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara, Guadalajara, Jalisco, Mexico
The Dauten Family Center for Bipolar Treatment Innovation at Massachusetts General Hospital, Boston, Massachusetts, United States
Clinical Research Facility, Royal Victoria Infirmary, Newcastle upon Tyne, Tyne and Wear, United Kingdom
Hepatology department - Hopital Saint Antoine, Paris, France
Academisch Medisch Centrum, Amsterdam, NH, Netherlands
Neuromusculare Research Unit, Rigshospitalet, Copenhagen, Denmark
Robarts Research Institute, London, Ontario, Canada
Jean Paul Bonnefont, Paris, France
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.